Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitrectomy plus intravitreal Ozurdex for idiopathic epimacular membrane
ChiCTR2100044228Phase 4Recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of ozurdex in Idiopathic epiretinal membrane (ERM) (2 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoints: vision and central macular thickness. Started Mar 2021; status: recruiting.
02
Drugs
ozurdex
03
Conditions
Idiopathic epiretinal membrane (ERM)
Beyond the preview
Go deeper on ChiCTR2100044228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044228.